Awareness of and receptivity to FDA's point-of-sale tobacco public education campaign

PLoS One. 2023 Jul 13;18(7):e0288462. doi: 10.1371/journal.pone.0288462. eCollection 2023.

Abstract

The purpose of the study was to assess awareness of and receptivity to FDA's point-of-sale (POS) tobacco public education campaign for adult cigarette smokers called Every Try Counts; it was the first multi-county POS campaign in the U.S. The design was a county-level treatment-control three-wave longitudinal design. The setting was 15 treatment and 15 control counties. Subjects were smokers ages 25 to 54 (N = 3,628). 4,145 individuals screened in as eligible; 3,628 (87.5% response rate) completed the Wave 1 questionnaire (Wave 2: n = 2,812; Wave 3: n = 2,571; retention 70.9%). Measures were self-reported brand and ad awareness (saw any ad a few times or more) and receptivity (5-item perceived effectiveness scale). The analysis included descriptive analyses of receptivity; bivariate analyses of awareness by treatment group; and covariate- and time-adjusted logistic regression models to determine changes in awareness attributable to the campaign. Receptivity was moderate and differed significantly by race/ethnicity. As was the case for all waves, at wave 3, ad awareness was significantly higher in treatment (53.3%) than control counties (36.1%, p < .05). In regression models, brand (OR = 1.53, 95% CI: 1.26-1.86) and ad (OR = 1.74, 95% CI: 1.39-2.16) awareness were significantly higher in treatment than control counties. Every Try Counts generated a moderate level of receptivity and attention from cigarette smokers. Limitations include self-reports of campaign awareness and generalizability to a small number of U.S. counties.

MeSH terms

  • Adult
  • Awareness
  • Health Promotion
  • Humans
  • Smokers
  • Smoking
  • Tobacco Products*

Grants and funding

LMD, MCF, and BB received funding from the United States Food and Drug Administration [contract number HHSF223201610032I] to complete this work. The funder, via employees of the FDA, contributed to the study design, data collection and analysis, decision to publish, and preparation of the manuscript.